See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: Sept. 7, 2006

Diabetic Neuropathy Sexual Dysfunction Bipolar Disorders

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Diabetic Neuropathy

This is a research study of an investigational drug to treat diabetic peripheral neuropathic pain. Volunteers 18-75 with diabetes mellitus (type 1 or type 2) who have daily pain due to diabetic neuropathy for at least six months but not more than five years and are willing to self-monitor blood glucose may be eligible.

The research sites are in California, Florida, and Texas.

More information

Please see http://www.centerwatch.com/patient/studies/cat253.html.

-----

Sexual Dysfunction

This study will evaluate the effectiveness and safety of an investigational medication for hypoactive sexual desire disorder (HSDD). Participants will receive study medication, medical exams, and lab tests at no cost. Financial compensation for time and travel may also be available. To learn more, visit www.DecreasedSexualDesire.com or call 1-877-899-8787.

The research site is in Billings, Mont.

More information

Please see http://www.centerwatch.com/patient/studies/cat333.html.

-----

Bipolar Disorders

This study will evaluate the safety and effectiveness of ziprasidone in treating people with depression associated with bipolar I disorder. Candidates at least 18 who currently feel depressed and who have been hospitalized for a manic episode may qualify.

The research site is in Riverside, Calif.

More information

Please see http://www.centerwatch.com/patient/studies/cat20.html.

-----

Copyright 2006 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.